Two Sigma Investments LP Sells 49,600 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Two Sigma Investments LP lessened its position in iShares Biotechnology ETF (NASDAQ:IBB) by 17.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 234,607 shares of the financial services provider’s stock after selling 49,600 shares during the period. Two Sigma Investments LP’s holdings in iShares Biotechnology ETF were worth $31,017,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in IBB. Bank of America Corp DE lifted its holdings in iShares Biotechnology ETF by 6.5% during the 4th quarter. Bank of America Corp DE now owns 7,489,427 shares of the financial services provider’s stock valued at $990,177,000 after purchasing an additional 460,154 shares during the last quarter. Main Management ETF Advisors LLC grew its stake in iShares Biotechnology ETF by 3.2% during the fourth quarter. Main Management ETF Advisors LLC now owns 612,180 shares of the financial services provider’s stock worth $80,936,000 after buying an additional 18,810 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of iShares Biotechnology ETF during the fourth quarter worth approximately $55,010,000. Gray Foundation increased its holdings in shares of iShares Biotechnology ETF by 25.2% during the fourth quarter. Gray Foundation now owns 164,872 shares of the financial services provider’s stock worth $21,798,000 after buying an additional 33,179 shares in the last quarter. Finally, Avalon Trust Co raised its stake in shares of iShares Biotechnology ETF by 0.7% in the fourth quarter. Avalon Trust Co now owns 127,893 shares of the financial services provider’s stock valued at $16,909,000 after acquiring an additional 935 shares during the last quarter. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of IBB opened at $124.67 on Wednesday. The company has a market capitalization of $5.37 billion, a P/E ratio of 23.96 and a beta of 0.77. iShares Biotechnology ETF has a one year low of $107.43 and a one year high of $150.57. The business’s 50 day simple moving average is $123.38 and its 200-day simple moving average is $132.45.

iShares Biotechnology ETF Increases Dividend

The firm also recently disclosed a dividend, which was paid on Friday, March 21st. Shareholders of record on Tuesday, March 18th were given a $0.1212 dividend. This is an increase from iShares Biotechnology ETF’s previous dividend of $0.06. The ex-dividend date of this dividend was Tuesday, March 18th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.